Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript
11:56pm, Thursday, 13'th Mar 2025
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer Da
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
04:02pm, Thursday, 13'th Mar 2025
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (Allo
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
08:30am, Monday, 03'rd Mar 2025
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (Allo
Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities
10:52am, Wednesday, 26'th Feb 2025
Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases, offering off-the-shelf therapies that reduce costs and treatment times. Cema-cel, Allogene's leading prod
Allogene Therapeutics Announces Participation in March Investor Conference
08:30am, Wednesday, 26'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
10:53pm, Monday, 24'th Feb 2025
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
02:10pm, Thursday, 26'th Dec 2024
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Thursday, 26'th Dec 2024
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
08:50am, Tuesday, 24'th Dec 2024
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 16'th Dec 2024
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
08:30am, Thursday, 12'th Dec 2024
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?
02:20pm, Monday, 02'nd Dec 2024
The dip in ALLO's share price can be attributed to strategic changes in its pipeline, which delayed bringing its lead drug to market by at least two years.
